ARTICLE | Clinical News
Vevesca: Pivotal
February 20, 2001 8:00 AM UTC
OGS said preliminary analysis of a six-month, 36-patient pivotal study showed Vevesca oral N-butyldeoxynojirimycin glucosyltransferase inhibitor alone successfully maintained Gaucher disease patients ...